{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T04:41:47Z","timestamp":1792644107546,"version":"4.5.0"},"reference-count":43,"publisher":"Wiley","issue":"s6","license":[{"start":{"date-parts":[[2006,11,10]],"date-time":"2006-11-10T00:00:00Z","timestamp":1163116800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Haemophilia"],"published-print":{"date-parts":[[2006,12]]},"abstract":"<jats:p><jats:bold>Summary.\u2002<\/jats:bold> The formation of alloantibodies against factor VIII (FVIII) or factor IX (FIX) is the most severe complication of replacement therapy in patients with haemophilia. In the last decade, genetic factors have been shown to constitute a decisive risk determinant for the development of inhibitors. In severe haemophilia A and B, mutations that result in an absent or truncated FVIII\/FIX protein are associated with a 20\u201380% risk of inhibitor formation. In mild to moderate haemophilia, missense mutations represent the main mutation type, with an inhibitor prevalence of 5%. These patients synthesize some endogenous, although non\u2010functional protein that is sufficient to induce immune tolerance. However, in patients with missense mutations clustered in the A2 and C2 domains (C1\/C2 junction), the risk of inhibitor formation is fourfold greater than in patients with mutations outside this region, indicating that inhibitor prevalence in missense mutations is also dependent on localization of the mutation. Recently, a significant association between inhibitor formation and polymorphisms in genes coding for cytokines (IL\u201010) and other immunoregulatory factors (TNF\u2010<jats:italic>\u03b1<\/jats:italic>) has been shown. These genetic factors constitute the individual genetic risk profile of a haemophilic patient. This risk is imprinted and fixed; however, environmental factors such as treatment schedule may increase or decrease the inhibitor risk in an individual patient. Improved understanding of these complex interactions may lead to the development of preventive measures to minimize inhibitor formation.<\/jats:p>","DOI":"10.1111\/j.1365-2516.2006.01361.x","type":"journal-article","created":{"date-parts":[[2006,11,10]],"date-time":"2006-11-10T14:06:14Z","timestamp":1163167574000},"page":"15-22","source":"Crossref","is-referenced-by-count":211,"title":["Genetic risk factors for inhibitors to factors VIII and IX"],"prefix":"10.1111","volume":"12","author":[{"given":"J.","family":"OLDENBURG","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"PAVLOVA","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2006,11,10]]},"reference":[{"key":"e_1_2_7_2_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-2007-1000659"},{"key":"e_1_2_7_3_2","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1097\/00001721-199310000-00012","article-title":"Incidence of inhibitors in haemophiliacs. A review of the literature","volume":"4","author":"Scharrer I","year":"1993","journal-title":"Blood Coagul Fibrinolysis"},{"key":"e_1_2_7_4_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminhematol.2003.11.016"},{"key":"e_1_2_7_5_2","doi-asserted-by":"publisher","DOI":"10.1002\/humu.1380050102"},{"key":"e_1_2_7_6_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-0038-1649954"},{"key":"e_1_2_7_7_2","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1055\/s-0037-1613931","article-title":"Relationship between factor VIII mutation type and inhibitor development in a cohort of previously untreated patients treated with recombinant factor VIII (recombinate). Recombinate PUP study group","volume":"83","author":"Goodeve AC","year":"2000","journal-title":"Thromb Haemost"},{"key":"e_1_2_7_8_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-0037-1615061"},{"key":"e_1_2_7_9_2","doi-asserted-by":"publisher","DOI":"10.1097\/00043426-199701000-00003"},{"key":"e_1_2_7_10_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-09-3918"},{"key":"e_1_2_7_11_2","unstructured":"AstermarkJ OldenburgJ PavlovaA BerntorpE LefvertAK.A bi\u2010allelic polymorphism at \u2212308 in the promoter region of the TNF\u2010\u03b1gene influences the risk of inhibitor development in patients with hemophilia.WHF Congress Vancouver 2006 abstract."},{"key":"e_1_2_7_12_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1351-8216.2001.00134.x"},{"key":"e_1_2_7_13_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2516.2001.00510.x"},{"key":"e_1_2_7_14_2","first-page":"924","article-title":"Genetic defects and inhibitor development in siblings with severe hemophilia A","volume":"90","author":"Astermark J","year":"2005","journal-title":"Haematologica"},{"key":"e_1_2_7_15_2","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1055\/s-0037-1615871","article-title":"The role of genetics in inhibitor formation","volume":"82","author":"Gill JC","year":"1999","journal-title":"Thromb Haemost"},{"key":"e_1_2_7_16_2","first-page":"162","article-title":"Recombinant FVIII (Kogenate) treatment of previously untreated patients (PUPs) with haemophilia A. Update of safety, efficacy and inhibitor development after seven study years. ISTH florence","author":"Lusher J","year":"1997","journal-title":"Thromb Haemost"},{"key":"e_1_2_7_17_2","first-page":"228","article-title":"Safety and immunogenicity of recombinant factor VIII (recombinate) in previously untreated patients (PUPs). A 7.3\u2003year update. WFH The Hague","volume":"4","author":"Gruppo R","year":"1998","journal-title":"Haemophilia"},{"key":"e_1_2_7_18_2","first-page":"239","article-title":"Increased frequency of inhibitors in African American haemophilia A patients. ASH Nashville","author":"Addiego J","year":"1994","journal-title":"Blood"},{"key":"e_1_2_7_19_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2516.1999.00300.x"},{"key":"e_1_2_7_20_2","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/26.1.216"},{"key":"e_1_2_7_21_2","first-page":"657","article-title":"Characterization of the factor VIII defect in 147 patients with sporadic hemophilia A: family studies indicate a mutation type\u2010dependent sex ratio of mutation frequencies","volume":"58","author":"Becker J","year":"1996","journal-title":"Am J Hum Genet"},{"key":"e_1_2_7_22_2","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1055\/s-0038-1656068","article-title":"Factor VIII Ise (R2159 C) in a patient with mild haemophilia A, an abnormal factor VIII with retention of function but modification of C2 epitopes","volume":"77","author":"Suzuki H","year":"1997","journal-title":"Thromb Haemost"},{"key":"e_1_2_7_23_2","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1182\/blood.V96.3.958","article-title":"A novel cause of mild\/moderate haemophilia A: mutations scattered in the factor VIII C1 domain reduce factor VIII binding to von Willebrand factor","volume":"96","author":"Jacquemin M","year":"2000","journal-title":"Blood"},{"key":"e_1_2_7_24_2","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1182\/blood.V96.3.979","article-title":"Haemophilic factor VIII C1\u2010 and C2\u2010domain missense mutations and their modeling to the 1.5\u2010angstrom human C2\u2010domain crystal structure","volume":"96","author":"Liu ML","year":"2000","journal-title":"Blood"},{"key":"e_1_2_7_25_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2516.1998.440558.x"},{"key":"e_1_2_7_26_2","doi-asserted-by":"crossref","first-page":"2267","DOI":"10.1182\/blood.V93.7.2267","article-title":"Antifactor VIII antibody inhibiting allogeneic but not autologous factor VIII in patients with mild hemophilia A","volume":"93","author":"Peerlinck K","year":"1999","journal-title":"Blood"},{"key":"e_1_2_7_27_2","doi-asserted-by":"publisher","DOI":"10.1159\/000204029"},{"key":"e_1_2_7_28_2","first-page":"635","article-title":"Molecular genotyping of the Italian cohort of patients with hemophilia B","volume":"90","author":"Belvini D","year":"2005","journal-title":"Haematologica"},{"key":"e_1_2_7_29_2","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/26.1.265"},{"key":"e_1_2_7_30_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-0037-1614081"},{"key":"e_1_2_7_31_2","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1055\/s-0038-1650515","article-title":"T lymphocyte proliferative responses induced by recombinant factor VIII in hemophilia A patients with inhibitors","volume":"76","author":"Singer ST","year":"1996","journal-title":"Thromb Haemost"},{"key":"e_1_2_7_32_2","first-page":"791","article-title":"Immunochemical characterization of antibodies to factor VIII in hemophilic and nonhemophilic patients","volume":"97","author":"Allain JP","year":"1981","journal-title":"J Lab Clin Med"},{"key":"e_1_2_7_33_2","first-page":"73","article-title":"Immunochemical characterization of factor VIII inhibitors","volume":"150","author":"Hoyer LW","year":"1984","journal-title":"Prog Clin Biol Res"},{"key":"e_1_2_7_34_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-0037-1615873"},{"key":"e_1_2_7_35_2","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1182\/blood.V95.4.1324.004k25_1324_1329","article-title":"Prevention and treatment of factor VIII inhibitors in murine hemophilia A","volume":"95","author":"Qian J","year":"2000","journal-title":"Blood"},{"key":"e_1_2_7_36_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-065X.1996.tb00703.x"},{"key":"e_1_2_7_37_2","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.immunol.14.1.233"},{"key":"e_1_2_7_38_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-0038-1655945"},{"key":"e_1_2_7_39_2","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1055\/s-0038-1655944","article-title":"HLA class II profile: a weak determinant of factor VIII inhibitor development in severe haemophilia A. UKHCDO inhibitor working party","volume":"77","author":"Hay CR","year":"1997","journal-title":"Thromb Haemost"},{"key":"e_1_2_7_40_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00172063"},{"key":"e_1_2_7_41_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2005.01375.x"},{"key":"e_1_2_7_42_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.89.5.1890"},{"key":"e_1_2_7_43_2","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.iy.10.040192.002211"},{"key":"e_1_2_7_44_2","doi-asserted-by":"publisher","DOI":"10.1016\/0167-5699(92)90107-I"}],"container-title":["Haemophilia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2516.2006.01361.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2516.2006.01361.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,26]],"date-time":"2023-09-26T12:19:19Z","timestamp":1695730759000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2516.2006.01361.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,11,10]]},"references-count":43,"journal-issue":{"issue":"s6","published-print":{"date-parts":[[2006,12]]}},"alternative-id":["10.1111\/j.1365-2516.2006.01361.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2516.2006.01361.x","archive":["Portico"],"relation":{},"ISSN":["1351-8216","1365-2516"],"issn-type":[{"value":"1351-8216","type":"print"},{"value":"1365-2516","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,11,10]]}}}